Vivek Subbiah: Tissue-agnostic precision medicine takes the spotlight!

Vivek Subbiah shared a post on his LinkedIn page:

“Hot off the press- Friday Motivation! Excited to announce our latest publication in the American Society of Clinical Oncology (ASCO) Journal of Clinical Oncology Precision Oncology (JCOPO) showcasing “Exceptional Responses to Selpercatinib in RET Fusion–Driven Metastatic Pancreatic Cancer”. Tissue-agnostic precision medicine takes the spotlight!”

For details, click here.
Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.